FDA 483 - Takeda Pharmaceutical Company Limited - September 18, 2015
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Takeda Pharmaceutical Company Limited's Osaka Plant in Japan revealed two significant observations related to human drug manufacturing. The firm was cited for incomplete laboratory records regarding process simulations, specifically the justification for using a particular substance, and for inadequate viewing capabilities of sterile product manufacturing processes, hindering proper inspection and monitoring of aseptic techniques. These issues raise concerns about the integrity of their aseptic processing and quality control unit.
ID · 9c0e3946-dc59-44ef-8197-c818f2754b5f